ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone781-345-9001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$78.11 million
Profitability
Miscellaneous
Employees350
OptionableNot Optionable
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS Inc (NASDAQ:CFMS) issued its earnings results on Wednesday, October, 31st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.08. The medical instruments supplier had revenue of $28.98 million for the quarter, compared to analyst estimates of $19.21 million. ConforMIS had a negative net margin of 51.25% and a negative return on equity of 90.97%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What guidance has ConforMIS issued on next quarter's earnings?
ConforMIS issued an update on its FY 2018 earnings guidance on Wednesday, October, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $77.5-78 million, compared to the consensus revenue estimate of $80.34 million.
What price target have analysts set for CFMS?
5 equities research analysts have issued 12-month price objectives for ConforMIS's stock. Their predictions range from $2.50 to $3.00. On average, they expect ConforMIS's share price to reach $2.8750 in the next twelve months. This suggests a possible upside of 396.5% from the stock's current price. View Analyst Price Targets for ConforMIS.
What is the consensus analysts' recommendation for ConforMIS?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.
What are Wall Street analysts saying about ConforMIS stock?
Here are some recent quotes from research analysts about ConforMIS stock:
- 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (11/5/2018)
- 2. BTIG Research analysts commented, "Ongoing OUS Headwinds While CFMS 2Q18 results were a bit below our expectations (rev. of $19.1M (+3% Y/Y,+2% xFx) vs. BTIG/Consensus of $19.3M/$19.4M respectively, product rev. increased Y/Y for the first time since 1Q17, growing 5% to $18.0M. Mgmt. is making progress on US commercialization (albeit slower than investors will prefer). OUS continues to be challenged in Germany but mgmt. noted recent OUS sales leadership hires that may open up a few countries in 2H18. Mgmt. commentary on payor acceptance of CFMS products indicates increasing positive traction amongst some payers but CFMS is still not where it wants to be on rep growth, which missed the 20% growth target slightly. On the call, mgmt. announced plans to reduce OpEx while shuffling its product pipeline around." (8/2/2018)
Has ConforMIS been receiving favorable news coverage?
News stories about CFMS stock have trended neutral this week, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ConforMIS earned a news impact score of 0.1 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of ConforMIS's key competitors?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 52)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 54)
- Dr. Daniel Steines M.D., MS, Consultant (Age 49)
- Mr. Ed Kilgallen, VP of Operations
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 52)
When did ConforMIS IPO?
(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $0.5790.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $36.64 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe.
What is ConforMIS's official website?
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
